Article
IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers.
JHEP reports : innovation in hepatology - 1 Aug 2026
Tesini Giulia, Greaves Jack, Knight Olivia, Shand Holly, Ammirabile Angela, McHaffie Sophie, Milne Jen, Ibrahim Halima, Meenan Rosemary, Campbell Sophia, Henderson Margaret, Lampis Andrea, Chesler Louis, Casadei-Gardini Andrea, Rimassa Lorenza, Christie Alan, Kendall Timothy J, Braconi Chiara
Abstract excerpt
BACKGROUND & AIMS: Targeted therapies for biliary tract cancers (BTC) are approved in the second-line setting. We investigated response to first-line platinum-based palliative systemic anti-cancer treatment in patients with the most common druggable alterations to determine the optimal positioning of targeted therapies in the treatment algorithm. METHODS: Patients treated at the Beatson West of Scotland...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.